Anokion Expands Leadership Team with Appointment of Deborah Geraghty, Ph.D., as Chief Business Officer

Stephan Kontos, Ph.D., promoted to Chief Scientific Officer

Tony Rossomando, Ph.D., appointed Vice President, Technical Operations

LAUSANNE, Switzerland, & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anokion (“Anokion” or the “Company”), a privately held biopharmaceutical
company developing novel tolerance-inducing therapeutics for autoimmune
diseases, today announced that Deborah Geraghty, Ph.D., former senior
vice president, corporate strategy at Dimension Therapeutics, Inc., has
been appointed chief business officer. Dr. Geraghty will join the
executive leadership team and her role will include business and
corporate development, strategic planning, program management, and
communications. In addition, Stephan Kontos, Ph.D., co-founder and
currently vice president of research, has been promoted to chief
scientific officer, and Tony Rossomando, Ph.D., has been hired as vice
president, technical operations.

“We are thrilled that Deb is joining the leadership team at Anokion,”
said John Hohneker, M.D., president and chief executive officer of
Anokion. “She is a highly regarded biopharma executive with a strong
track record in creating new, innovative companies and building
portfolios of important novel therapies through pipeline development and
strategic transactions. With Deb’s addition, the promotion of Stephan to
CSO, and Tony’s appointment, the team is well-positioned to realize the
potential of Anokion’s innovative and advancing pipeline, offering the
potential for meaningful clinical benefit to patients living with severe
autoimmune diseases.”

Dr. Geraghty stated, “It’s an exciting time to join Anokion. As our
immune tolerance platforms have matured, they have shown strong promise
in treating diseases for which there remain significant unmet medical
need. I look forward to contributing to the potential we have at hand to
realize this new wave of innovation and the offer of new hope for
patients and their families.”

Dr. Geraghty brings 20 years of extensive experience in the life
sciences industry, serving in senior strategic, commercial, and
portfolio positions. At Dimension, she played a lead role in the
company’s Series B financing and initial public offering, and was
responsible for driving growth of the company’s portfolio prior to its
successful IPO and recent acquisition by Ultragenyx Pharmaceutical Inc.
Previous to Dimension, Dr. Geraghty was founder and vice president,
project and portfolio development at Cydan Development, an orphan drug
accelerator that raised $26 million to identify and de-risk assets with
therapeutic and commercial potential. Prior, Dr. Geraghty was head of
portfolio advancement at Aileron Therapeutics, where she led strategic
growth and commercial efforts, and was director, new product marketing,
at Infinity Pharmaceuticals. She also founded Back Bay Strategies, and
held multiple positions at Kendall Strategies, Feinstein Kean
Healthcare, and Genzyme Corp. Dr. Geraghty serves on the medical and
scientific advisory board of Global Genes, a leading rare disease
patient advocacy organization. She earned a B.S. in Biology at Union
College, an MBA from the Carroll School at Boston College, and a Ph.D.
in Molecular Biology at the University of Vermont.

Stephan Kontos, Ph.D., a co-founder of Anokion, assumes the role of
chief scientific officer from Jeff Hubbell, Ph.D., who will transition
to chief scientific advisor for the Company. Dr. Kontos brings more than
10 years of drug and platform discovery experience and will lead all
aspects of research, discovery, and platform development at Anokion. He
co-invented and translated the Company’s tolerance technology platform
having served most recently as vice president of research. Dr. Kontos
has published numerous peer-reviewed research articles in top tier
journals, including Science Advances and PNAS, and is an
inventor on multiple patents and patent applications. Dr. Kontos
received his B.Sc. in Chemical Engineering from the University of Texas
at Austin and moved to the Swiss Federal Institute of Technology in
Lausanne for his Ph.D. in Bioengineering.

Tony Rossomando, Ph.D., joins Anokion as vice president of technical
operations and leads all aspects of the company’s CMC activities. Dr.
Rossomando brings over 25 years of industry experience to Anokion and
most recently was head of analytical development at Alexion, following
its acquisition of Synageva Biopharma, where he oversaw the entire
pipeline of development stage projects through phase 2. Prior to
Synageva, Dr. Rossomando held positions of increasing responsibility at
Alnylam Pharmaceuticals, Biogen, and Bayer Corp. He was instrumental in
two successful IND submissions for neuropathic pain and
mucopolysaccharidosis IIIB and played a pivotal role in the approval of
Kanuma® for Lysosomal Lipase Deficiency in the United States, Europe,
and Japan. Dr. Rossomando received his B.S. from SUNY Stony Brook and
his Ph.D. in microbiology from the University of Virginia and completed
post-doctoral training at Cold Spring Harbor where he focused on
cell-signaling control mechanisms and protein sciences.

About Anokion

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne
(EPFL), is focused on applying the company’s antigen-specific immune
tolerance technology to treat autoimmune and allergic diseases and
reduce the immunogenicity of therapeutic proteins. As a platform
technology, Anokion’s approach to antigen-specific immune tolerance can
be translated to virtually any protein in numerous clinical indications.
Anokion’s investors include Versant Ventures, Novo Ventures, Novartis
Venture Fund and a group of individual investors. For more information,
please visit


Deb Geraghty, Ph.D., +1 857-320-6635